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Bacillus anthracis is the causative agent of anthrax, a disease that affects wildlife, livestock, and humans.
Protection against anthrax is primarily afforded by immunity to the B. anthracis protective antigen (PA),
particularly PA domains 4 and 1. To further the development of an orally delivered human vaccine for mass
vaccination against anthrax, we produced Salmonella enterica serovar Typhimurium expressing full-length PA,
PA domains 1 and 4, or PA domain 4 using codon-optimized PA DNA fused to the S. enterica serovar Typhi ClyA
and under the control of the ompC promoter. Oral immunization of A/J mice with Salmonella expressing
full-length PA protected five of six mice against a challenge with 105 CFU of aerosolized B. anthracis STI spores,
whereas Salmonella expressing PA domains 1 and 4 provided only 25% protection (two of eight mice), and
Salmonella expressing PA domain 4 or a Salmonella-only control afforded no measurable protection. However,
a purified recombinant fusion protein of domains 1 and 4 provided 100% protection, and purified recombinant
4 provided protection in three of eight immunized mice. Thus, we demonstrate for the first time the efficacy of
an oral S. enterica-based vaccine against aerosolized B. anthracis spores.
Bacillus anthracis is the causative agent of anthrax, a disease
that affects wildlife, livestock, and humans. The ability of B.
anthracis to cause disease is dependent on the production of a
polyglutamic acid capsule, which provides resistance to phago-
cytosis and to the production of anthrax toxins. The toxins
consist of three proteins—protective antigen (PA), edema fac-
tor (EF), and lethal factor (LF)—which act in binary combi-
nations (20). PA and EF together produce the edema toxin,
whereas PA and LF together produce the lethal toxin. Protec-
tion against anthrax is considered to be due mainly to the
immune response to PA. Specifically, research into mecha-
nisms associated with the efficacy of current anthrax vaccines
has led to the conclusion that PA is essential and a dominant
component of the vaccines since the protein can elicit effective
protective immunity in the absence of LF and EF (19, 26).
The current licensed United Kingdom and U.S. anthrax vac-
cines for human use consist of cell-free filtrates of a nonencap-
sulated but toxigenic B. anthracis derivative, adsorbed to alum
(U.S. vaccine) or aluminum hydroxide (United Kingdom vac-
cine). Although effective in animal studies, these vaccines must be
administered by needle in multiple doses over several months,
with annual boosters to maintain continuous protection (1). In
addition to occasional cases of adverse local reactions, the vac-
cines are expensive to produce, have a limited shelf life as a
consequence of their formulation, and are currently only available
to military personnel. There is a need to develop vaccines capable
of protecting both military and civilian populations, which poses
challenges in terms of the general health of these populations,
compliance, and the ability to mass vaccinate in the event of an
attack. Therefore, improvements to increase the efficacy, longev-
ity, and safety of the anthrax vaccine are warranted. A subunit
vaccine consisting of purified recombinant PA protein adsorbed
to aluminum hydroxide has been proposed (24) but will suffer
from the drawbacks of limited ambient stability and the need
to be administered by needle.
One approach to the development of an improved next-
generation anthrax vaccine involves the use of live attenuated
Salmonella vaccines to deliver PA. This approach offers a num-
ber of advantages (12). First, live Salmonella vaccines can be
given orally (the natural route of infection), enabling a nonin-
vasive route of vaccine administration. Second, both mucosal
and systemic immune responses can be elicited, which may be
important for protection against airborne infection. In addi-
tion, live attenuated Salmonella vaccines are able to simulate
both humoral and cellular immune responses that may be
important for protection against disease. Since the live atten-
uated Salmonella vaccine strain Ty21a (14) is licensed for hu-
man use and other next-generation attenuated Salmonella
strains are in clinical trials (12), it should also be possible to
develop safe recombinant Salmonella vaccines for licensure.
Finally, since Salmonella is genetically tractable, recombinant
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Salmonella vaccines are relatively easy to develop and are also
relatively cost-effective to produce.
Preliminary studies evaluating the use of attenuated Salmo-
nella for delivery of PA have been reported (4, 13). Initially,
PA was expressed in Salmonella from a high-copy-number
plasmid, leading to high-levels of PA in vitro but plasmid
instability in vivo and low colonization of the host tissues by the
bacteria (4). More recently, a lower-copy-number plasmid was
used to express PA as a fusion to the Escherichia coli hemolysin
(Hly) export system in order to enable export of the expressed
PA protein from the Salmonella (13). This plasmid was also
found to be unstable, perhaps as a consequence of the high
metabolic load placed upon the bacteria in continuously pro-
ducing both the Hly export proteins and PA. However, when
the Hly-PA fusion was integrated into the Salmonella chromo-
some, the resulting recombinant was able to provide protection
against an injected anthrax spore challenge if administered via
the intravenous route and not by the oral route.
We considered a number of approaches that would allow us
to realize our goal of devising an orally delivered Salmonella
vaccine which would provide protection against airborne B.
anthracis. The use of an inducible promoter to selectively ex-
press PA in vivo coupled with a stabilized plasmid-based ex-
pression system would promote an enhanced immune re-
sponse. In addition, we considered that expression only of the
domains of PA which are associated with protective immunity
(6) could allow the generation of a more stable recombinant.
Recently, Galen et al. described the use of the S. enterica
serovar Typhi cytolysin A (ClyA) export system for delivery of
a domain of PA in Salmonella, improving the immunogenicity
of PA compared to cytoplasmic expression (11). This ClyA
export apparatus requires only the fusion of proteins to the
34-kDa ClyA protein, making it attractive and simple to use for
the secretion of proteins from Salmonella.
In the present study, attenuated Salmonella strains express-
ing PA, domain 4 of PA, or a fusion protein of domains 1 and
4 of PA were produced and compared for immunogenicity and
protective efficacy against aerosolized B. anthracis spores.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. S. enterica serovar Typhi-
murium SL3261 (aroA mutant), an attenuated amino acid-dependent strain, and
S. enterica serovar Typhimurium LB5010, used for methylation of E. coli-derived
plasmids prior to transformation of strain SL3261, were taken from laboratory
stocks (Dstl Porton Down, United Kingdom). E. coli TOP10F or E. coli DH5
cells (Invitrogen) were used for plasmid maintenance and E. coli BL21(DE3)/
pLYsS cells were used for protein expression. Plasmid pVDL9.3PA83ec encod-
ing an E. coli codon-optimized PA gene of B. anthracis (13) was used as a
template DNA for PCR. The pCR2.1-TOPO plasmid vector (Invitrogen, United
Kingdom) was used to clone PCR products. Plasmid pGEX-6-P3 (Amersham-
Pharmacia) was used to express proteins as fusions to N-terminal glutathione
S-transferase (GST). Bacterial strains were cultured aerobically on Luria agar or
in Luria broth supplemented with ampicillin (100 g/ml), kanamycin (10 g/ml),
or chloramphenicol (25 g/ml), as appropriate, at 37°C and with agitation at 180
to 200 rpm or statically. Similarly, strain SL3261 was routinely supplemented
with 1% (vol/vol) “aromix” comprising 4 mg of phenylalanine/ml, 4 mg of tryp-
tophan/ml, 1 mg of para-aminobenzoic acid (PABA)/ml and 1 mg of dihydroxy-
benzoic acid/ml (adapted from Chatfield et al. [3]).
The growth rates of the recombinant Salmonella strains were determined by
culturing the bacteria for 24 h in Luria broth containing antibiotic selection and
enumerating them on Luria agar containing antibiotics. To establish the stability
of the strains in vitro, the recombinant bacteria were cultured over 72 h, with
passage every 24 h, in the absence of antibiotic (equivalent to culturing the
bacteria for approximately 44 generations), and the stability of the plasmids
within the Salmonella was calculated by enumeration of bacteria on Luria agar
with or without antibiotic selection. Inocula were produced by culturing the
recombinant Salmonella strains statically overnight at 37°C, harvesting the bac-
teria by centrifugation (7,000  g for 20 min at 4°C), and then washing and
resuspending the bacteria in sterile phosphate-buffered saline (PBS). The inoc-
ulum dose was verified by plating serial dilutions of each culture on Luria agar
supplemented with antibiotic, where appropriate.
Mice. Female A/Jola (A/J) mice (supplied and used at 8 to 12 weeks of age;
Harlan UK, Ltd.) were used for all studies since these mice provide a consistent
mouse model for infection with a toxigenic nonencapsulated (Tox Cap) strain
of B. anthracis (32). All animal procedures strictly adhered to the Animals
(Scientific Procedures) Act of 1986.
Construction of recombinant Salmonella strains expressing PA domains. All
methods for DNA manipulation were carried out according to the method of
Sambrook et al. (29) unless otherwise stated. Taq DNA polymerase (Invitrogen)
or Vent DNA polymerase (New England Biolabs) were used in the PCRs.
(i) Construction of expression plasmid pSEC10. A new expression plasmid was
derived by using the origin of replication from pSC101 (2), which normally exists at
five copies per chromosomal equivalent. The primers used are listed in Table 1, and
the essential plasmids created from these primers are listed in Table 2. First, an
ori101 replication cassette was synthesized by PCR using primers 1 and 2 with
pSC101 as a template, generating a 1,949-bp BamHI-AvrII fragment. This frag-
ment was inserted into the pBR322-derivative pGEN2, cleaved with BglII-AvrII
to create pGEN4. The authenticity of this PCR product was confirmed by
nucleotide sequencing the cloned DNA. Construction of pGEN132 was accom-
plished by removal of the ori101 cassette from pGEN4 as a 2,638-bp BamHI
fragment and insertion into pJN5 digested with BglII and BamHI, thereby
regenerating the gfpuv gene encoding the green fluorescent protein allele GFPuv
(BD Biosciences/Clontech) under an osmotically controlled PompC promoter.
Final assemblage of a pSC101-derived expression plasmid containing a complete
plasmid maintenance system (9) was achieved by introduction of parA from
TABLE 1. Primers used in this study
Primer Oligonucleotide sequencea Template
1 5-GTCTGCCGGATTGCTTATCCTGGCGGATCCGGTTGACAGTAAGACGGGTAAGCCTG
TTGAT-3
pSC101
2 5-CCTAGGTTTCACCTGTTCTATTAGGTGTTACATGCTGTTCATCTGTTACATTGTCGAT
CTG-3
pSC101
PA83/F1 5-CACGCTAGCGAAGTAAAGCAAGAGAACCGTCTGC-3 pVDL9.3PA83ec
PA83/R1 5-CACGCTAGCACCGATCTCGTAACCTTTCTTGGAG-3 pVDL9.3PA83ec
DOM4/F2 5-CACGCTAGCTTCCACTACGATCGTAATAACATCGC-3 pVDL9.3PA83ec
DOM1/R2 5-CACGCTAGCCGCAGCAACCAGTGGATGGCGTG-3 pVDL9.3PA83ec
LINK/F1 5-TTCCACTACGATCGTAATAACATCGC-3 pVDL9.3PA83ec
LINK/R1 5-GATGTTATTACGATCGTAGTGGAAGGCAGCTGGACCTGGACCCGCAGCAACCAGTGG
ATGGCGTGCTT-3
pVDL9.3PA83ec
PA83/F4 5-GTGTTGGGATCCGAAGTAAAGCAAGAGAACCGTCTG-3 pVDL9.3PA83ec
PA83/R4 5-GTGTTGCTCGAGTTATTAACCGATCTCGTAACCTTTCTTGGA-3 pVDL9.3PA83ec
a Boldface type denotes a linker sequence(s). Underlining denotes a region cleaved by restriction endonucleases.
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pJN8. A 4,469-bp BamHI-SpeI cassette from pJN8 containing bla, hok-sok, and
parA was ligated to the 2,649-bp BamHI-SpeI ori101 cassette from pGEN132 to
regenerate gfpuv and create pGEN206. The -lactamase cassette of pGEN206
was replaced by partial cleavage with SpeI, complete digestion with XbaI, and
replacement of the resulting 1,181-bp bla gene with a previously described
1,046-bp NheI fragment encoding resistance to kanamycin (11), creating pEXO5.
Finally, the clyA cassette was cleaved from pSEC91 (11) as an XhoI-AvrII
fragment and ligated into pEXO5 digested with XhoI-AvrII to generate pSEC10.
(ii) Cloning of PA domains into pSEC10. An adaptation of a fusion PCR
protocol (18) was used to create a 1,212-bp fusion of DNA encoding PA domain
1 (PA1) and PA domain 4 (PA4). First, the PA1 and PA4 domains were ampli-
fied separately in 50-l reactions using primers (PA83/F1 and LINK/R1 for PA1
and LINK/F1 and PA83/R1 for PA4; Table 1) designed to create a linker (GGC
AGC TGG ACC TGG ACC) between the individual domains with NheI restric-
tion digestion sites at the 5 end of PA1 and the 3 end of PA4. Plasmid
pVDL9.3PA83ec (13) was used as the DNA template. Subsequently, a 50-l
“fusion” PCR was prepared incorporating 1 l each of the PA1 and PA4 PCR
products and using the flanking primers PA83/F1 and PA83/R1 containing NheI
sites (Table 1). In addition, DNA encoding either PA4 and the full-length PA
gene (PA1-4) was PCR amplified using appropriate primers (DOM4/F2 and
PA83/R1 for PA4 and PA83/F1 and PA83/R1 for PA1-4; Table 1) containing
NheI sites. The resulting PCR products were cloned into the pCR2.1-TOPO
vector. Subsequently, the PA insert cassettes were cleaved from the TOPO
vectors as NheI subcloned into the NheI site of pSEC10, generating ClyA-PA
domain fusions downstream of the PompC promoter. The authenticity of all of the
PCR products detailed above was confirmed by nucleotide sequencing of the
appropriate cloned DNA.
(iii) Transformation of Salmonella. The pSEC10 derivatives were transformed
into E. coli, and individual transformants were screened for expression of the
ClyA-PA proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting of colony lysates (see below) and one pos-
itive clone for each plasmid construct was electroporated into S. enterica serovar
Typhimurium SL3261 via passage through S. enterica serovar Typhimurium
LB5010, an intermediate host strain required for methylation of the plasmid
DNA. In addition, plasmid pVDL9.3PA83ec, encoding full-length PA fused to
the Hly export system and conferring resistance to chloramphenicol (13), was
transformed into SL3261 for comparison.
Detection of PA expression. Recombinant Salmonella was cultured in L broth
supplemented with antibiotic selection for 24 h with agitation. Samples (1 ml)
were centrifuged at 13,000  g for 10 min, and the resulting cell pellets or
supernatants were diluted 1:1 in 2 Laemmli buffer then boiled for 5 min. The
samples were normalized to 3  108 CFU/ml for comparison. To evaluate PA
expression, SDS-PAGE on 12.5% (wt/vol) polyacrylamide gels (PhastSystem;
Amersham Pharmacia Biotech, Ltd.) and Western blotting on Immobilon-P
nitrocellulose membrane (Millipore) was performed. After transfer of proteins
from SDS-PAGE gels, membranes were blocked with PBS containing 2% (wt/
vol) bovine serum albumin (PBS-BSA), and then probed by using mouse anti-
PA4 antibody, 2D4J (produced at DSTL), and a rabbit anti-mouse horseradish
peroxidase-conjugated secondary antibody (Sigma-Aldrich). Antibodies were
used at 1:2,000 dilutions in PBS-BSA, and membranes were washed using PBS
containing 0.05% (vol/vol) Tween 20. Proteins were visualized by using Sigma-
Fast 3,3-diaminobenzidine tablets (DAB peroxidase substrate; Sigma-Aldrich).
Determination of plasmid stability in vivo. Groups of eight female A/J mice
were inoculated with approximately 1  109 to 3.8  109 CFU of SL3261 or
SL3261 recombinants orally by intragastric gavage. On day 8 postinoculation,
mice were culled by cervical dislocation and spleens and Peyer’s patches (six/
mouse) were harvested. The tissues were homogenized in 1 ml of sterile PBS
using 50-m-pore-size cell strainers (Becton Dickinson Labware) and subse-
quently inoculated onto agar plates with or without antibiotic selection to de-
termine counts of recombinants or total bacteria, respectively, in order to cal-
culate the stability of the plasmids in the Salmonella strains.
Production of PA14 protein. DNA encoding the PA14 fusion was PCR
amplified from the recombinant the pCR2.1-TOPO vector using primers
PA83/F4 and PA83/R4, containing XhoI and BamHI restriction sites (Table 1)
and then cloned into the XhoI/BamHI sites of the expression vector pGEX-6-P3
(GE Healthcare) downstream and in frame of the lac promoter, as a fusion to
GST. To produce purified recombinant GST-PA14 protein, the recombinant
plasmid was transformed into E. coli BL21(DES)/pLysS, and transformants were
cultured in Luria broth containing 50 g of ampicillin/ml, 30 g of chloram-
phenicol/ml, and 1% (wt/vol) glucose, followed by shaking at 37°C, to an A600 of
0.4 prior to induction with 1 mM IPTG (isopropyl--D-thiogalactopyranoside).
Cultures were then incubated for a further 4 h, followed by harvesting by cen-
trifugation at 10,000 rpm for 15 min. Cell pellets were resuspended in PBS and
sonicated four times for 20 s each time in an ice water bath, and the suspension
was centrifuged at 15,000  g for 30 min. Subsequently, cell supernatants were
loaded onto a 5-ml GSTrap 4B column (GE Healthcare) previously equilibrated
with PBS. The column was washed with PBS, and the fusion protein was eluted
with 20 mM reduced glutathione–50 mM Tris (pH 8). After analysis by SDS-
PAGE, fractions containing PA14 were pooled and dialyzed into cleavage
buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol; pH 7).
PreScission protease was added at a ratio of 2 U per 100 g of fusion protein,
followed by incubation overnight at room temperature. Cleaved PA14 protein
was separated from the GST by reapplying to a 5-ml GSTrap 4B column pre-
equilibrated with PBS. Unbound fractions containing protein were analyzed by
SDS-PAGE, pooled, and dialyzed against PBS. The PA14 protein concentra-
tion was determined by using a BCA assay (Pierce). Purified recombinant (r)
PA1, PA4, and PA1-4 were all produced using the same protocol as described
previously (6). Purified proteins were visualized by SDS-PAGE alongside appro-
priate Bio-Rad molecular weight markers.
Immune response analysis. Groups of five to eight mice were inoculated orally
by intragastric gavage with between 1  108 and 5  109 CFU of S. enterica
serovar Typhimurium SL3261 or SL3261 recombinants on days 0, 14, and 28.
Bacteria were centrifuged and resuspended in PBS before dosing. Alternatively,
mice were injected via the intramuscular route with 10 g of purified rPA
proteins absorbed to a 20% (vol/vol) solution of 1.3% Alhydrogel (Superfos
Biosector a/s, Vedback, Denmark). Subsequently, serum samples were evaluated
for immune response analyses.
(i) ELISA. Serum samples were tested for specific antibody responses by
enzyme-linked immunosorbent assay (ELISA) using standard procedures. Blood
samples were collected from the tail veins of all immunized and control mice on
days 13, 15, 46, and 73 after inoculations on days 0, 14, and 28 and serum was
assayed for PA-specific immunoglobulin G (IgG) antibody responses. Ninety-
six-well microtiter plates were coated with 5 g of recombinant PA/ml (produced
at Dstl [25]) overnight at 4°C and then washed. All washing steps were carried
out with PBS containing 0.02% (vol/vol) Tween 20. Plates were then blocked with
2% (wt/vol) skimmed milk in PBS for 1 h, and each serum sample was serially
diluted 1:2 in blocking solution across the plate, followed by a 1-h incubation.
Bound antibody was detected by using horseradish peroxidase-conjugated poly-
clonal goat anti-mouse IgG (Harlan Sera-lab) diluted 1:2,000 in blocking buffer
and incubated for 1 h. Plates were developed with 100 l of ABTS [2,2 azino-
bis(3-ethylbenzthiazolinesulfonic acid)]; Sigma-Aldridge) substrate, and the A414
of the plates were measured. All samples were assayed in duplicate. Endpoint
antibody titers were expressed as the maximum dilution of sample giving an
absorbance or more than 0.1 A414 units, after subtraction of the absorbance due
to nonspecific binding detected in control sera from mice immunized with the
parent S. enterica serovar Typhimurium SL3261 strain. The results are presented
as the reciprocal of the dilution, and the mean represented the average of
duplicate values for each samples.
(ii) TNA. The titer of toxin-neutralizing antibody (TNA) in immune sera was
determined based on the ability of the serum to inhibit the cytotoxicity of the
combination of PA with LF as described previously (28). Briefly, J774A.1 murine
macrophage cells (American Tissue Culture Collection) were harvested and
plated out at approximately 3.5  104 cells/well in a 96-well microtiter plate, and
40 to 60% confluent layers were allowed to form over a 17- to 19-h period at 37°C
in 5% (vol/vol) CO2 as viewed by microscopy. Antisera was prepared in a
separate 96-well plates and serially diluted down the plate. A positive control
reference sera with a known 50% effective dose was also included, and a non-
specific mouse antisera was used as a negative control. Then, 100 l of anthrax
TABLE 2. Selected plasmids used in this study
Plasmid Size(kb) Relevant genotype
Source or
reference
pJN5 3.1 oriE1 gfpuv bla 8
pJN8 5.4 oriE1 gfpuv bla hok-sok parA 8
pGEN2 4.2 oriE1 gfpuv tetA hok-sok 8
pSC101 9.3 ori101 tetA par 1
pGEN4 5.6 ori101 gfpuv tetA hok-sok This study
pGEN132 4.8 ori101 gfpuv bla par This study
pGEN206 7.1 ori101 gfpuv bla par hok-sok parA This study
pEXO5 7.0 ori101 gfpuv aph par hok-sok parA This study
pSEC91 7.6 ori15A clay tetA aph hok-sok par parA 9
pSEC10 7.2 ori101 clyA aph hok-sok par parA This study
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lethal toxin was added (50 ng of PA/ml and 40 ng of LF/ml) per well, and the
plates were incubated for 30 min. Medium was then removed from the J774A.1
cells, and the antiserum-toxin mix was added to the plates (100 l/well). These
were subsequently incubated for 4 h at 37°C in 5% (vol/vol) CO2. Cell viability
was determined by the addition of 25 l of 5 mg of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Sigma)/ml dissolved in PBS (Gibco). Through-
out the assay, wells containing positive and negative controls were randomly
checked via microscopy to check cell viability visually; negative control wells
contained small, rounded, dead cells, and positive control wells contained living,
healthy cells, as expected. The incubation was continued for a further 2 h under
the same conditions, and then the reaction was stopped by the addition of a 20%
(wt/vol) SDS (Becton-Dickinson) dissolved in 50% (vol/vol) DMF (Becton-Dick-
inson) in water (Gibco). Plates were then incubated for 16 to 20 h at 37°C in 5%
(vol/vol) CO2. The optical density readings of the plates were taken by using
MultisKan Ascent microplate photometer (Thermo Labsystems) at 570 and 690
nm as a reference filter. Endpoints were calculated by using SAS software
(version 8.2), running an endpoint calculation algorithm developed by the Cen-
ters for Disease Control and Prevention. The TNA endpoint is defined as the
reciprocal of the serum dilution that gives 50% neutralization of the anthrax
lethal toxin, corresponding to the inflection point of a four-parameter logistic-log
fit of the neutralization curve. All antisera were tested at least twice by two
separate analysts; the results shown are the averages of each individual 50%
effective dose from each separate assay performed by each analyst.
B. anthracis spore preparation. B. anthracis STI (Tox Cap) was cultured on
the surface of Roux bottles containing New Sporulation medium (3.0 g of Difco
Trypton, 6.0 g of Oxoid bacteriological peptone, 3.0 g Oxoid yeast extract, 1.5 g
of Oxoid Lab Lemco, 1 ml of 0.1% MnCl2  4H2O, and 25 g of Difco Bacto agar
in 1 liter of distilled H2O) at 37°C until the cultures contained more than 95%
phase bright spores, measured by phase-contrast microscopy; typically, incuba-
tion of between 7 to 10 days resulted in 95% phase bright spores. Spores were
harvested by centrifugation at 10,000  g for 10 min and then washed 10 times
with ice-cold distilled water to remove any vegetative cells and cell debris. The
spore preparation was heated at 70°C for 1 h to kill any remaining vegetative
cells, and the final spore concentration was determined by serial dilution. Spore
preparations were stored at 20°C until required.
Challenge with aerosolized B. anthracis spores. Aerosol exposure was carried
out by using a Henderson-type apparatus (17) and Collison spray (22). Briefly,
10-ml aliquots of STI spores were suspended in sterile distilled water at a
concentration of up to 109 CFU/ml, and 3 drops of Antifoam 289 (Sigma) was
added just before each preparation was placed in the Collison spray. Groups of
mice (heads only) were exposed for 10 min to an air stream containing an aerosol
of STI spores generated by the Collison spray and conditioned by the Hender-
son-type apparatus. The concentration of STI spores in the aerosol was deter-
mined by taking samples from the exposure chamber with an all-glass impinger
(23) containing sterile distilled water and then plating diluted impinger samples
onto nutrient agar to determine the number of spores per liter. The respiratory
volume of the animals was calculated by the method of Guyton (15) and the
actual dose inhaled and retained in the lungs was calculated by the method of
Harper and Morton (16).
Initially, to identify a challenge dose with which to evaluate the Salmonella
vaccine candidates, a small dose-finding study was carried out. Briefly, groups of
four to five mice were exposed to B. anthracis STI, giving calculated retained
doses of approximately 66 CFU, 4.7  102 CFU, 5.3  103, or 6.3  104 CFU.
Subsequently, at 9 weeks after the final immunizing dose with Salmonella mice
were challenged with B. anthracis STI spores via the aerosol route with a calcu-
lated retained dose of approximately 105 CFU for all groups (ranging between
8.5  104 and 1.4  105 CFU). This is equivalent to approximately 200 median
lethal doses by this route (6). The challenge experiment was carried out blinded.
Animals were closely observed for 14 days after challenge to determine their
protected status. Humane endpoints were strictly observed so that any animal
that displayed a collection of clinical signs that indicated a lethal infection
(piloerection, posture [hunching], and mobility problems) was culled.
Statistical analysis. One-way analysis of variance with Tukey’s multiple com-
parison postanalysis test and statistical analysis of survival using the GraphPad
Prism version 3.02 for Windows (GraphPad Software, San Diego, CA) were
performed.
RESULTS
Construction of Salmonella expressing ClyA-PA fusion pro-
teins. Proteins fused to the carboxyl terminus of the S. enterica
serovar Typhi ClyA export apparatus can be expressed at a
high level in Salmonella and could be transported out of the
bacterial cell without causing lysis (10). Thus, in the present
study we chose to evaluate ClyA as an export mechanism for
known protective domains of PA expressed in Salmonella. Ini-
tially, a plasmid expression vector, pSEC10, was constructed
that contained the gene encoding ClyA downstream of the
PompC promoter. This plasmid is similar to those previously
described by Galen et al. (11) and also included the hok-sok
postsegregational killing locus and the parA gene encoding an
active partitioning system. A fusion PCR protocol was followed
to create a fusion between domain 1 of PA (PA1) and domain
4 of PA (PA4) and the resulting PA14 fusion was cloned into
the expression plasmid pSEC10 as a fusion to ClyA, resulting in
plasmid pSECPA14 (Fig. 1). Similar constructs producing ClyA
fused to PA4 and full-length PA were also produced and termed
pSECPA4 and pSECPA1-4, respectively. The recombinant plas-
mids containing the ClyA-PA fusions were subsequently trans-
formed into S. enterica serovar Typhimurium SL3261 by electro-
poration (resulting in strains SL3261/pSECPA14, SL3261/
pSECPA4, and SL3261/pSECPA1-4). In vitro expression of the
ClyA-PA fusion proteins from the strains was detected by SDS-
PAGE and Western blotting in whole-cell lysates with a PA4-
specific antibody (Fig. 2). However, the ClyA-PA fusion proteins
could not be detected in the culture supernatants using this
method.
FIG. 1. PA expression plasmids. (A) Cloning of PA fragments into
NheI sites of pSEC10 as fusions to the ClyA gene. (B) General struc-
ture of pSEC10-based plasmids encoding PA gene fragments: SL3261/
PSECPA1-4 encoding domains 1 to 4 of PA, SL3261/pSECPA14
encoding domain 1 and domain 4 of PA, and SL3261/pSECPA4 en-
coding domain 4 of PA.
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Growth and stability of recombinant Salmonella strains. The
S. enterica serovar Typhimurium SL3261 recombinants con-
taining pSEC10 and pSEC10 derivatives were found to grow
similarly to the parental SL3261 strain when cultured in Luria
broth over 24 h (data not shown). Furthermore, in vitro, the
plasmids were stably maintained (80 to 100% plasmid reten-
tion) over 72 h in the absence of antibiotic selection. The in
vivo stability of the SL3261 recombinants was assessed by de-
termining the level of colonization of murine tissues. Eight
days after intragastric dosing of A/J mice with approximately
109 CFU of the SL3261 recombinants, the spleens and Peyer’s
patches were removed, and the level of colonization and sta-
bility of the bacteria in the tissues was assessed by plating
homogenized tissues onto selective or nonselective agar. Sim-
ilar levels of colonization of spleens by the SL3261 recombi-
nants were found (data not shown), and the plasmids were
stably maintained in all of the bacteria isolated from splenic
tissues. At the time point tested, the colonization of the Peyer’s
patches was low although, where there was colonization, the
SL3261 recombinants were generally stable. This indicated
that the infection had progressed to the deeper tissues such as
the spleen.
Immunogenicity of Salmonella strains expressing PA. The
immunogenicity of the SL3261 recombinants was assessed af-
ter intragastric dosing of A/J mice three times at 2-week inter-
vals with approximately 109 CFU of the bacteria. Serum sam-
ples were taken on day 13, 27, 45, or 73 and analyzed by ELISA
for PA-specific IgG responses. A progressive increase in PA-
specific IgG responses was detected over time in immunized
mice (data not shown). After only one or two doses of the
SL3261 recombinants, PA-specific IgG antibody responses
were generally low. However, on day 73, and prior to challenge
with B. anthracis spores, all of the mice immunized with Sal-
monella expressing PA or fragments of PA had developed
PA-specific IgG responses (Fig. 3A). Furthermore, analysis of
the sera by TNA demonstrated that antibodies capable of
neutralizing anthrax toxin were present in the sera from mice
immunized with the recombinant Salmonella (Fig. 3B). Differ-
ences in the magnitude of the anti-PA responses were ob-
served in individual mice within the groups, and some individ-
ual mice failed to show measurable PA-specific responses.
However, in mice showing responses, all groups showed statis-
tically similar toxin-neutralizing activity.
Immunogenicity of rPA proteins. An expression vector was
produced to allow the purification of the PA14 fusion pro-
tein, and the protein was subsequently purified (Fig. 4) and
used, along with rPA1-4, rPA4, and rPA1 (6), for immuniza-
tion of A/J mice as a comparison to the Salmonella vaccine
candidates. Specifically, 10 g of each recombinant protein was
administered along with the adjuvant Alhydrogel three times
at 2-week intervals, and serum samples were taken on days 13,
27, 45, and 73 for analysis of the PA-specific IgG responses by
ELISA. Similarly to the responses observed with the Salmo-
nella, at days 13, 27, and 45, progressive increases in PA-
specific IgG induced by the proteins could be detected (data
not shown). On day 73, ELISA of the sera from individual mice
showed that all of the recombinant proteins were able to in-
duce PA-specific IgG responses (Fig. 3C). The responses to
rPA1-4 and rPA14 were approximately 1 log greater than
those to rPA4 and rPA1 which, in turn, were greater than the
responses to the SL3261 derivatives. Analysis of the sera by
TNA demonstrated that the anthrax toxin-neutralizing activity
stimulated by the rPA1-4 and rPA14 proteins was also
greater than that induced by the Salmonella (Fig. 3D).
Protection of mice against an aerosolized B. anthracis chal-
lenge. Initially, an experiment was carried out to determine the
concentration of B. anthracis STI spores for use as a lethal
challenge to naive mice. Groups of four to five naive A/J mice
were exposed to retained doses of between 66 and 6.3  104
CFU of aerosolized B. anthracis spores and then monitored for
survival. Only the mice given the highest inoculum of 6.3  104
CFU completely succumbed to the challenge (data not shown).
Thus, this dose was considered the minimum challenge re-
quirement for the subsequent protection experiment.
Mice inoculated with the SL3261 recombinants or the puri-
fied recombinant proteins were challenged with approximately
105 CFU (equivalent to approximately 200 mean lethal doses) of
aerosolized B. anthracis STI spores and monitored for survival.
Naive mice and those given the SL3261 parental control strain
succumbed to infection within 6 days, and all mice receiving
SL3261/pSEC10, SL3261/pSECPA4, or SL3261/pVDL9.3PA83ec
died by day 7 postchallenge (Table 3). However, two of eight mice
immunized with SL3261/pSECPA14 were protected against
the challenge, and five of six mice inoculated with SL3261/
pSECPA1-4 also survived. Thus, SL3261/pSECPA1-4 expressing
the full-length PA protein as a fusion with ClyA afforded signif-
icant protection against aerosolized B. anthracis spore challenge
(P 	 0.01 compared to SL3261/pSEC10). Mice immunized with
rPA1-4, rPA14, or rPA4 were solidly protected against chal-
lenge, and immunization of mice with rPA1 protected two of six
mice from challenge with B. anthracis STI (Table 3).
FIG. 2. Expression of PA as ClyA fusions from Salmonella. Nor-
malized cell lysates (3  108 CFU/ml) and culture supernatants (either
neat or diluted 1:10 as indicated) from S. enterica serovar Typhi-
murium SL3261 recombinants were subjected to SDS-PAGE and
Western blotting with PA4-specific monoclonal antibody. Lane M,
Bio-Rad broad-range biotinylated SDS marker; lane 1, SL3261/
pSECPA1-4 1:10 cell pellet; lane 2, SL3261/pSECPA1-4 neat super-
natant; lane 3, SL3261/pSECPA14 1:10 cell pellet; lane 4, SL3261/
pSECPA14 neat supernatant; lane 5, SL3261/pSECPA4 1:10 cell
pellet; lane 6, SL3261/pSECPA4 neat supernatant; lane 7, SL3261/
pSEC10 1:10 cell pellet; lane 8, SL3261/pSEC10 neat supernatant; lane
9, 0.1 mg of rPA/ml.
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DISCUSSION
In order to develop an oral vaccine for anthrax using Sal-
monella as a vehicle to deliver PA, a sufficiently stable, immu-
nogenic vaccine candidate is required. We have constructed
and evaluated a recombinant Salmonella which contains a mul-
ticopy plasmid encoding codon-optimized PA in order to in-
crease the number of gene copies from which the PA protein
may be expressed. We have also incorporated the ClyA export
system for the direct export of PA. This approach has previ-
ously been used by Galen et al. (11) to export PA4 and requires
FIG. 3. Serum immune responses to PA. Serum samples were taken from A/J mice orally immunized three times at 2-week intervals with 1 
108 to 5  109 CFU of S. enterica serovar Typhimurium SL3261 or SL3261 recombinants (A and B) or intramuscularly immunized with 10 g of
PA protein adsorbed to a 20% (vol/vol) solution of Alhydrogel (C and D). Sera were used to determine the IgG (A or C) or TNA (B or D)
responses to PA.
FIG. 4. SDS-PAGE analysis of purified recombinant PA proteins.
Purified PA proteins (2 g per 10-l sample loaded) were subjected to
SDS-PAGE. Lane 1, Bio-Rad Kaleidoscope-prestained standards;
lane 2, rPA1; lane 3, rPA4; lane 4, rPA14; lane 5, rPA1-4; lane 6,
Bio-Rad low-range prestained standards.
TABLE 3. Survival of vaccinated mice challenged with aerosolized
B. anthracis STI sporesa
Inoculum No. of survivors/total no.
SL3261 ...........................................................................................0/8
SL3261/pSEC10 ............................................................................0/8
SL3261/PSECPA1-4 .....................................................................5/6
SL3261/pSECPA14 ...................................................................2/8
SL3261/pSECPA4.........................................................................0/8
SL3261/pVDL9.3PA83ec.............................................................0/6
rPA1-4............................................................................................8/8
rPA14..........................................................................................7/7
rPA4...............................................................................................8/8
rPA1...............................................................................................3/8
None ..............................................................................................0/7
a A/J mice were inoculated three times at 2-week intervals with 1  108 to 5 
109 CFU of S. enterica serovar Typhimurium SL3261 or SL3261 recombinants
delivered orally by intragastric gavage or 10 g of protein adsorbed to a 20%
(vol/vol) solution of Alhydrogel delivered by intramuscular injection. The mice
were subsequently challenged 9 weeks after the final dose via the intranasal route
with approximately 105 CFU of aerosolized B. anthracis STI spores and moni-
tored for survival until 14 days postexposure.
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only the coexpression of the 34-kDa ClyA protein. The
pSEC10 plasmid allowed the expression of PA under the con-
trol of the PompC promoter, in order to target expression to the
intracellular location. Since PA domains 1 and 4 are known to
possess protective epitopes, SL3261 derivatives expressing full-
length PA, a PA14 fusion protein, or PA4 only were pro-
duced.
Although studies by Wai et al. (31) indicated that the ClyA
protein accumulates in the periplasm and is subsequently ex-
ported from the bacterial cell via the release of outer mem-
brane vesicles from the cell surface, we were unable to show
that the ClyA-PA protein fusions were exported into the cul-
ture supernatants. However, PA expression was detected and
the SL3261 recombinants containing pSEC10-based plasmids
were found to be at least 80% stable in vitro and in vivo. The
pVDL9.3PA83ec plasmid, previously shown to be unstable in
S. enterica serovar Typhimurium strain Zoosaloral H (13), was
stably maintained in SL3261. This finding perhaps reflects,
generally, the relative stabilities of plasmids in different strains
of Salmonella.
Mice orally inoculated with SL3261 recombinants expressing
full-length PA, domain 4 only, or a fusion protein consisting of
domains 1 and 4 generated anthrax toxin-neutralizing antibod-
ies. The Western blot of the SL3261 recombinants probed with
anti-PA was prepared using standardized CFU/ml samples
(Fig. 2) indicated that full-length PA was not expressed at a
higher level in Salmonella than PA14 or PA4. Thus, it is
likely that the enhanced protective response induced after im-
munization with full-length PA is a result of the presence of
domains 2 and 3. This is consistent with the previous finding
that domain 2 is able to improve protection afforded by domain
1 (6). This could be due to the presence of additional protec-
tive epitopes or the role played by domains 2 and 3 in tertiary
conformation or protein export (30).
Mice orally immunized with SL3261 expressing the full-
length PA were protected (five of six mice) against a lethal
exposure to aerosolized B. anthracis spores. In comparison,
only two of eight mice given SL3261 expressing PA14 sur-
vived the exposure, whereas all of the mice given SL3261
expressing PA4 succumbed to infection. We believe that this is
the first report of the protection of aerosolized anthrax after
oral immunization with a Salmonella-based vaccine.
In the present study, we have also evaluated the ability of
purified PA protein, the individual domains PA1 or PA4, or
the PA14 fusion protein to protect mice against aerosolized
B. anthracis spores. When administered with Alhydrogel, all of
the proteins stimulated strong antigen-specific antibody re-
sponses. Although rPA4, rPA14, and rPA1-4 conferred com-
plete protection, rPA1 was only able to protect three of eight
animals. These data correspond with the finding that rPA1
provided a lower level of protection than rPA4 when chal-
lenged with B. anthracis by injection (6). It was not possible to
determine whether the purified recombinant fusion protein,
rPA14, offered a greater level of protection against anthrax
than rPA4 only. A higher challenge level may have allowed this
to be determined. However, the comparison of the Salmonella
recombinants indicated that PA14 is more protective than
PA1, supporting the evaluation of the fusion protein. Overall,
the results from the in vitro and in vivo protection studies
indicate that the optimum protective effect is obtained when
the full-length PA protein is used to develop the Salmonella-
based vaccine.
An important finding from the work reported here is the
poor correlation of serum antibody levels to PA with the de-
gree of protection against B. anthracis challenge. However,
when sera was tested in a toxin-neutralizing assay, a good
correlation was observed. Clearly, these findings suggest that
only a proportion of the antibody generated after immuniza-
tion is able to neutralize anthrax toxin, and immunogens that
are able to induce high levels of antibody will not necessarily
provide high levels of protection. Similar findings have recently
been reported by Duc et al. (5).
The aim of this research is ultimately to develop an orally
delivered vaccine for anthrax. In the present study, we have
shown for the first time that orally administered Salmonella
expressing PA is able to protect mice against infection caused
by airborne B. anthracis. However, the development of a vac-
cine suitable for use in humans would be dependent on the
expression of PA in S. enterica serovar Typhi. Depending on
the immunogenicity of this recombinant, it may be more ap-
propriate to use this vaccine to boost existing responses that
have been primed at an earlier date. Such an orally delivered
booster vaccine would be valuable when it is necessary to
ensure that large populations rapidly develop protective im-
munity. Work to construct S. enterica serovar Typhi expressing
PA, using the systems we have reported here, is currently
under way.
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